Inventiva Shares Fall by 5.12% on Friday, October 10
The share price of the biopharmaceutical company specializing in the development of oral therapies for the treatment of MASH closed at €3.9850, significantly down from the previous day.
Market Dynamics and Recent Company Developments
The stock lost 5.12% this Friday, dropping from €4.20 to €3.9850, with trading volume representing 0.46% of the capital. This downward movement is part of a challenging short-term trend, with a cumulative drop of 23.37% over the last seven days. The CAC 40 also fell by 1.53% to 7,918 points, not immune to the selling pressure of the session, but the magnitude of the movement on Inventiva was significantly greater. Over a broader horizon, the performance remains remarkable: the stock has shown a growth of 174.8% over twelve months, compared to only 4.73% for the Paris index. This massive outperformance contrasts with the brutal consolidation observed in recent days. Regarding recent context, several events have marked the company's news. On October 1, Inventiva announced the appointment of Andrew Obenshain as CEO, replacing Frédéric Cren, the company's co-founder. This strategic transition aims to prepare for potential commercialization in the United States, a key market for MASH. At the end of September, the company published its financial results for the first half of 2025, showing a cash position of 122.1 million euros and an extended financing horizon until the end of 2026. The main results of the Phase 3 NATiV3 study are expected in the second half of 2026. These announcements, although strategically significant, have not been enough to support the share price in recent days.
Technical Analysis and Stock Performance
Technically, the stock has broken below its support threshold at €4.20, which precisely matches the previous day's closing price. This slight breach indicates intensifying selling pressure. The Relative Strength Index (RSI) is at 43, signaling a weakening of momentum without yet reaching a pronounced oversold zone. This positioning reflects a hesitant market, where sellers temporarily take the upper hand without buyers completely capitulating. Concurrently, the MACD, which measures the convergence and divergence of moving averages, shows a signal line slightly above the MACD line itself, with a negative histogram at -0.08. This setup indicates a slowdown in the bullish momentum observed in recent weeks, or even a beginning of a short-term reversal. The monthly volatility of the stock, measured at 17.61%, remains high, explaining the amplitude of recent movements. However, with a beta of 0.27, Inventiva shows significantly lower sensitivity to fluctuations in the CAC 40, which limits its exposure to index movements. The stock is now trading below its 50-day moving average, set at €4.22, but remains well above its 200-day moving average, established at €3.09. This configuration illustrates a positive long-term trend, despite an ongoing technical correction. The Bollinger Bands, ranging from €4.17 to €5.34, frame recent variations and suggest a consolidation phase after the strong rise in recent months. The Chaikin Money Flow, negative at -0.16, confirms a weakening of buying flows, while the negative On-Balance Volume indicates dominant selling pressure on recent volumes.
